


Appendix A

Claim Amendments

1. (Currently amended) ~~Compounds~~ A compound of formula I,



in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl,

either, in a first embodiment (embodiment a) ~~according to~~
~~the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl,
hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or
predominantly fluorine-substituted 1-4C-alkyl, and

R5 is hydrogen or 1-4C-alkyl,

or, in a second embodiment (embodiment b) ~~according to the~~
~~present invention,~~

R4 is hydrogen or 1-4C-alkyl, and

R5 is -O-R51, in which

R51 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl,
hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or
predominantly fluorine-substituted 1-4C-alkyl,

Har is optionally substituted by R6 and/or R7 and/or R8, and
is a 5- to 10-membered monocyclic ~~monocyclic~~ or fused
bicyclic unsaturated or partially saturated heteroaryl
radical comprising 1 to 4 heteroatoms independently

selected ~~independently~~ from the group consisting of oxygen, nitrogen and sulfur, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, -A-N(R61)R62, pyridyl, or completely or partially fluorine-substituted 1-4C-alkyl, in which

A is a bond or 1-4C-alkylene,

R61 is hydrogen or 1-4C-alkyl,

R62 is hydrogen or 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is optionally substituted by R611, and is a 3- to 7-membered saturated or unsaturated monocyclic heterocyclic ring radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one to three further heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, in which

R611 is 1-4C-alkyl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, hydroxyl, oxo, amino or mono- or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds.~~

2. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl,

either, in a first embodiment (embodiment a) ~~according to~~
~~the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl,
hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or
predominantly fluorine-substituted 1-4C-alkyl, and

R5 is hydrogen or 1-4C-alkyl,

or, in a second embodiment (embodiment b) ~~according to the~~
~~present invention,~~

R4 is hydrogen or 1-4C-alkyl, and

R5 is -O-R51, in which

R51 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl,
hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or
predominantly fluorine-substituted 1-4C-alkyl,

Har is optionally substituted by R6 and/or R7 and/or R8, and
is a 5- to 10-membered monocyclic ~~monocyclic~~ or fused
bicyclic unsaturated or partially saturated heteroaryl
radical comprising 1 to 4 heteroatoms independently
selected ~~independently~~ from the group consisting of
oxygen, nitrogen and sulfur, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, -A-N(R61)R62, pyridyl, or completely or partially fluorine-substituted 1-4C-alkyl, in which

A is a bond or 1-4C-alkylene,

R61 is hydrogen or 1-4C-alkyl,

R62 is hydrogen or 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

Het1 is optionally substituted by R611, and is a 3- to 7-membered saturated or unsaturated monocyclic heterocyclic ring radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one to three further heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, in which

R611 is 1-4C-alkyl,

R7 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, hydroxyl, amino or mono- or di-1-4C-alkylamino,

R8 is halogen,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the salts, the N oxides and the salts of the N oxides
of these compounds.~~

3. (Currently amended) ~~Compounds~~ A compound of formula I
according to claim 1 in which

R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy,
3-5C-cycloalkylmethoxy, 2,2-difluoroethoxy, or
completely or predominantly fluorine-substituted
1-2C-alkoxy,

R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy,
3-5C-cycloalkylmethoxy, 2,2-difluoroethoxy, or
completely or predominantly fluorine-substituted
1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen, [[];]

either, in a first embodiment (embodiment a) ~~according to
the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

or, in a second embodiment (embodiment b) ~~according to the present invention,~~

R4 is hydrogen, and

R5 is -O-R51, in which

R51 is hydrogen or 1-4C-alkylcarbonyl, [[;]]

wherein in one embodiment detail ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7, and is a 9- or 10-membered fused bicyclic partially saturated heteroaryl radical comprising a heteroatom-free benzene ring and, in the other ring, 1 or 2 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur,

whereby said Har ring system is attached to the parent molecular group via any substitutable carbon atom of the benzene ring,

in which

R6 is 1-4C-alkyl or halogen,

R7 is halogen, [[;]]

or, in another embodiment detail ~~according to this invention,~~

Har is Cyc2, in which

Cyc2 is optionally substituted by R6 and/or R7 and/or R8,

and is a 9- or 10-membered fused bicyclic fully aromatic ring system containing one to four heteroatoms each of which is selected from the group consisting of nitrogen, oxygen and sulphur, and which Cyc2 ring system is made up of a first constituent (constituent m) being a benzene or pyridine ring,

and fused to said first constituent m,

a second constituent (constituent n) being a 5- or 6-membered monocyclic ~~monocyclic~~ heteroaryl ring comprising one to three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur,

whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable ring carbon atom of the constituent m,

in which

R6 is 1-4C-alkyl or 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

R8 is 1-4C-alkyl, [[;]]

or, in yet another embodimental detail ~~according to this invention,~~

either

Har is optionally substituted by R6 and/or R7 and/or R8, and is a 6-membered monocyclic unsaturated heteroaryl ~~heteroaryl~~ radical comprising one or two nitrogen atoms, or

Har is optionally substituted by R6 and/or R7, and is a 5-membered monocyclic unsaturated heteroaryl ~~heteroaryl~~ radical comprising one to four heteroatoms independently selected ~~independently~~ from the group consisting of oxygen, nitrogen and sulphur,

in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, cyano, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, -A-N(R61)R62, or pyridyl, in which

A is a bond or 1-4C-alkylene,

R61 is hydrogen or 1-4C-alkyl,

R62 is hydrogen or 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either, in one facet,

Het1 is optionally substituted by R611 on a ring nitrogen atom, and is a 5- to 7-membered saturated monocyclic heterocyclic ring radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one further heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, in which

R611 is 1-4C-alkyl,

or, in another facet,

Het1 is a 5-membered unsaturated monocyclic heteroaryl radical comprising the nitrogen atom, to which R61 and R62 are bonded, and optionally one to three further nitrogen atoms,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, 1-4C-alkylthio, sulfanyl, hydroxyl, oxo, amino, or mono- or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

4. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen, [[;]]

either, in a first embodiment (embodiment a) ~~according to the present invention,~~

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

or, in a second embodiment (embodiment b) ~~according to the present invention,~~

R4 is hydrogen, and

R5 is -O-R51, in which

R51 is hydrogen or 1-4C-alkylcarbonyl, [[;]]

wherein in one embodimental detail ~~according to this invention,~~

Har is Cyc1, in which

Cyc1 is optionally substituted by halogen on its benzene ring, and is indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, 3,4-dihydrobenzo[1,4]oxazinyl, 1-methyl-indolinyl, 2-methyl-isoindolinyl, 1-methyl-tetrahydroquinolinyl, 2-methyl-tetrahydroisoquinolinyl, 4-methyl-3,4-dihydrobenzo[1,4]oxazinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, benzo[1,3]dioxolyl, dihydrobenzo[1,4]dioxinyl, chromanyl, chromenyl, or 2,2-difluoro-benzo[1,3]dioxolyl,

whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable carbon atom of the benzene ring, **[[;]]**

or, in another embodimental detail ~~according to this invention,~~

Har is Cyc2, in which

Cyc2 is optionally substituted by R6 and/or R7 and/or R8, and is a 9- or 10-membered fused bicyclic fully aromatic ring system containing one to three heteroatoms each of which is selected from the group consisting of

nitrogen, oxygen and sulphur, and which Cyc2 ring system is made up of

a first constituent (constituent m) being a benzene or pyridine ring,

and fused to said first constituent m,

a second constituent (constituent n) being a 5- or 6-membered monocyclic ~~monocyclic~~ heteroaryl ring comprising one to three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur,

whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable ring carbon atom of the constituent m,

in which

R6 is 1-4C-alkyl or 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

R8 is 1-4C-alkyl, [[;]]

or, in yet another embodimental detail ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which

A is a bond or 1-4C-alkylene,

R61 is 1-4C-alkyl,

R62 is 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl or 4N-methylpiperazin-1-yl,

or

Het1 is pyrrol-1-yl, pyrazol-1-yl, triazol-1-yl or imidazol-1-yl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, hydroxyl, oxo, or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy, **[[;]]**

or, in still yet another embodimental detail ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7, and is a 5-membered monocyclic unsaturated heteroaryl ~~heteroaryl~~ radical comprising one to four heteroatoms independently selected ~~independently~~ from the group consisting of oxygen, nitrogen and sulphur,

in which

R6 is 1-4C-alkyl, or pyridyl,

R7 is 1-4C-alkyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

5. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

one of R1 and R2 is methoxy or ethoxy, and the other is methoxy, ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl, and

R5 is hydrogen,

in one embodimental detail ~~according to this invention,~~

Har is Cyc1, in which

Cyc1 is optionally substituted by chlorine on its benzene ring, and is indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, or 3,4-dihydrobenzo[1,4]oxazinyl, 1-methyl-indolinyl, 2-methyl-isoindolinyl, 1-methyl-tetrahydroquinolinyl, 2-methyl-tetrahydroisoquinolinyl, or 4-methyl-3,4-dihydrobenzo[1,4]oxazinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothiophenyl, benzo[1,3]dioxolyl, dihydrobenzo[1,4]dioxinyl, chromanyl, chromenyl, or 2,2-difluoro-benzo[1,3]dioxolyl,

whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable carbon atom of the benzene ring, **[[:]]**

or, in another embodimental detail ~~according to this invention,~~

Har is Cyc2, in which

Cyc2 is optionally substituted by R6 and/or R7, and is either
pyrazolopyridinyl or 1-methyl-pyrazolopyridinyl,

whereby these radicals may be attached to the parent molecular group via the pyridine ring,

or

benzothiazolyl, benzoxazolyl, benzimidazolyl,
indazolyl, 1-methyl-benzimidazolyl, 1-methyl-
indazolyl, benzoxadiazolyl, benzotriazolyl, 1H-methyl-
benzotriazolyl, benzothiadiazolyl, quinolinyl,
isoquinolinyl, quinoxalinyl, quinazolinyl or
cinnolinyl,

whereby these radicals may be attached to the parent molecular group via the benzene ring,

in which

R6 is 1-4C-alkyl or 1-4C-alkoxy,

R7 is 1-4C-alkoxy, **[[]]**

or, in yet another embodimental detail ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7 and/or R8,
and is a pyridinyl, pyrimidinyl, pyrazinyl or
pyridazinyl radical, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, 1-
4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-
N(R61)R62, in which

A is a bond or 1-4C-alkylene,

R61 is 1-4C-alkyl,

R62 is 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl or 4N-methyl-piperazin-1-yl,

or

Het1 is pyrrol-1-yl, pyrazol-1-yl, triazol-1-yl or imidazol-1-yl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, hydroxyl, oxo, or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy, [[;]]

or, in still yet another embodimental detail ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7, and is a 5-membered monocyclic unsaturated heteroaryl ~~heteroaryl~~ radical comprising one to four heteroatoms independently

selected ~~independently~~ from the group consisting of
oxygen, nitrogen and sulphur,

in which

R6 is 1-4C-alkyl, or pyridyl, .

R7 is 1-4C-alkyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or
enantiomer thereof

~~and the enantiomers, as well as the salts, the N-oxides and
the salts of the N-oxides of these compounds and
enantiomers.~~

6. (Currently amended) ~~Compounds~~ A compound of formula I
according to claim 1 in which

R1 is methoxy or ethoxy,

R2 is methoxy, ethoxy, 2,2-difluoroethoxy or
difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen or acetyl, and

R5 is hydrogen,

in one embodimental detail ~~according to this invention,~~

Har is Cyc1, in which

Cyc1 is benzo[1,3]dioxol-5-yl, dihydrobenzo[1,4]dioxin-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, or 5-chloro-4-methyl-3,4-dihydrobenzo[1,4]oxazin-7-yl, [[;]]

or, in another embodimental detail ~~according to this invention,~~

Har is Cyc2, in which

Cyc2 is quinolin-6-yl, benzofurazan-5-yl, benzothiazol-6-yl, 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl, benzo[1,2,3]thiadiazol-5-yl or quinoxalin-5-yl, [[;]]

or, in yet another embodimental detail ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which

R6 is chlorine, methyl, methoxy, ethoxy, methylthio, methoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which

A is a bond or ethylene,

R61 is methyl,

R62 is methyl,
or R61 and R62 together and with inclusion of the nitrogen
atom, to which they are attached, form a heterocyclic
ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl or morpholin-4-yl,
or

Het1 is pyrazol-1-yl or imidazol-1-yl,

R7 is methyl, methoxy, ethoxy, methylthio or dimethylamino,

R8 is chlorine or methoxy, **[[;]]**

or, in still yet another embodimental detail ~~according to~~
~~this invention,~~

Har is isoxazolyl, 1-methylimidazolyl, or pyridyl-thiazolyl,
[[;]]

or a salt, enantiomer, N-oxide, salt of an N-oxide or
enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and~~
~~the salts of the N oxides of these compounds and~~
~~enantiomers.~~

7. (Currently amended) ~~Compounds~~ A compound of formula I
according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen or acetyl, and

R5 is hydrogen,

in one embodimental detail ~~according to this invention,~~

Har is Cyc1, in which

Cyc1 is benzo[1,3]dioxol-5-yl, dihydrobenzo[1,4]dioxin-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, or 5-chloro-4-methyl-3,4-dihydrobenzo[1,4]oxazin-7-yl, [[;]]

or, in another embodimental detail ~~according to this invention,~~

Har is Cyc2, in which

Cyc2 is quinolin-6-yl, benzofurazan-5-yl, benzothiazol-6-yl, 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl, benzo[1,2,3]thiadiazol-5-yl or quinoxalin-5-yl, [[;]]

or, in yet another embodimental detail ~~according to this invention,~~

Har is pyridin-3-yl, pyridin-4-yl, 6-(morpholin-4-yl)-pyridin-3-yl, 6-(piperidin-1-yl)-pyridin-3-yl, 6-(pyrazol-1-yl)-pyridin-3-yl, 6-(imidazol-1-yl)-pyridin-3-yl, 6-methoxycarbonyl-pyridin-3-yl, 3-methoxycarbonyl-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-3-yl, 2-methylsulfanyl-pyridin-3-yl, 6-hydroxy-pyridin-3-yl, 6-carboxy-pyridin-3-yl, pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-pyrimidin-5-yl, pyrazin-2-yl, 5-methyl-pyrazin-2-yl, 6-[2-(pyrrolidin-1-yl)-ethyl]-pyridin-3-yl, 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 4-methyl-2-methylsulfanyl-pyrimidin-5-yl, 5-chloro-2-methylsulfanyl-pyrimidin-4-yl, 4-chloro-2-dimethylamino-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, 3,6-dimethoxy-pyridazin-4-yl, 4-chloro-2,6-dimethoxy-pyridin-3-yl, 3-chloro-2,6-

dimethoxy-pyridin-4-yl, 5-chloro-2,6-bisdimethylamino-
pyrimidin-4-yl, or 2,4,6-trimethoxy-pyrimidin-5-yl,
[[;]]

or, in still yet another embodimental detail ~~according to~~
~~this invention,~~

Har is isoxazol-5-yl, 1-methylimidazol-2-yl, 1-
methylimidazol-5-yl, or 2-(pyridin-3-yl)-thiazol-4-yl,
[[;]]

or a salt, enantiomer, N-oxide, salt of an N-oxide or
enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and~~
~~the salts of the N oxides of these compounds and~~
~~enantiomers.~~

8. (Currently amended) ~~Compounds~~ A compound of formula I
according to claim 1 in which

R1 is methoxy,

R2 is ethoxy, 2,2-difluoroethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen,

in one embodimental detail ~~according to this invention,~~

Har is Cyc1, in which

Cyc1 is benzo[1,3]dioxol-5-yl, dihydrobenzo[1,4]dioxin-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, or 5-chloro-4-methyl-3,4-dihydrobenzo[1,4]oxazin-7-yl, **[[;]]**

or, in another embodimental detail ~~according to this invention,~~

Har is Cyc2, in which

Cyc2 is quinolin-6-yl, benzofurazan-5-yl, benzothiazol-6-yl, 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl, benzo[1,2,3]thiadiazol-5-yl or quinoxalin-5-yl, **[[;]]**

or, in yet another embodimental detail ~~according to this invention,~~

Har is pyridin-3-yl, pyridin-4-yl, 6-(morpholin-4-yl)-pyridin-3-yl, 6-(piperidin-1-yl)-pyridin-3-yl, 6-(pyrazol-1-yl)-pyridin-3-yl, 6-(imidazol-1-yl)-pyridin-3-yl, 6-methoxycarbonyl-pyridin-3-yl, 3-methoxycarbonyl-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-

3-yl, 2-methylsulfanyl-pyridin-3-yl, 6-hydroxy-pyridin-3-yl, 6-carboxy-pyridin-3-yl, pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-pyrimidin-5-yl, pyrazin-2-yl, 5-methyl-pyrazin-2-yl, 6-[2-(pyrrolidin-1-yl)-ethyl]-pyridin-3-yl, 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 4-methyl-2-methylsulfanyl-pyrimidin-5-yl, 5-chloro-2-methylsulfanyl-pyrimidin-4-yl, 4-chloro-2-dimethylamino-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, 3,6-dimethoxy-pyridazin-4-yl, 4-chloro-2,6-dimethoxy-pyridin-3-yl, 3-chloro-2,6-dimethoxy-pyridin-4-yl, 5-chloro-2,6-bisdimethylamino-pyrimidin-4-yl, or 2,4,6-trimethoxy-pyrimidin-5-yl, [[;]]

or, in still yet another embodimental detail ~~according to this invention,~~

Har is isoxazol-5-yl, 1-methylimidazol-2-yl, 1-methylimidazol-5-yl, or 2-(pyridin-3-yl)-thiazol-4-yl,
 [[;]]

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

9. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 ~~[[or 2]]~~ in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

in one embodimental detail (detail 1) ~~according to this invention,~~

Har is optionally substituted by R6 and/or R7, and is
benzo[1,4]dioxanyl or benzo[1,3]dioxolyl, in which

R6 is fluorine,

R7 is fluorine, [[;]]

or, in another embodiment detail (detail 2) ~~according to~~
~~this invention,~~

Har is quinolinyl, benzofurazanyl or benzothiazolyl, [[;]]

or, in yet another embodiment detail (detail 3) ~~according~~
~~to this invention,~~

either

Har is optionally substituted by R6 and/or R7, and is
pyridinyl, in which

R6 is 1-4C-alkoxy, -A-N(R61)R62, in which

A is a bond,

R61 and R62 together and with inclusion of the nitrogen
atom, to which they are attached, form a heterocyclic
ring Het1, in which

Het1 is morpholinyl, thiomorpholinyl, N-(R611)-piperazinyl
or 4-N-(R611)-homopiperazinyl, in which

R611 is 1-2C-alkyl,

R7 is 1-4C-alkoxy,

or

Har is optionally substituted by R6, and is isoxazolyl, imidazolyl or thiazolyl, in which

R6 is 1-4C-alkyl or pyridyl, [[;]]

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds.~~

10. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen, [[;]]

in one embodimental detail ~~according to this invention,~~

Har is Cycl, in which

Cyc1 is dihydrobenzo[1,4]dioxinyl, benzo[1,3]dioxolyl or
2,2-difluoro-benzo[1,3]dioxolyl,

~~such as e.g. dihydrobenzo[1,4]dioxin-6-yl,~~

~~benzo[1,3]dioxol-5-yl, or 2,2-difluoro-benzo[1,3]dioxol-5-yl,~~

or, in another embodimental detail ~~according to this~~
~~invention,~~

Har is Cyc2, in which

either

Cyc2 is quinolinyl, benzofurazanyl or benzothiazolyl,

~~such as e.g. quinolin-6-yl, benzofurazan-5-yl or~~

~~benzothiazol-6-yl,~~

or

Cyc2 is 1-(1-4C-alkyl)-1H-benzotriazolyl or 1-(1-4C-alkyl)-

4-methoxy-3-methyl-1H-pyrazolo[3,4-b]pyridinyl,

~~such as e.g. 1-methyl-1H-benzotriazol-5-yl or 4-methoxy-~~

~~1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl,~~

or, in yet another embodimental detail ~~according to this~~
~~invention,~~

either

Har is pyridinyl, pyrimidinyl, isoxazolyl, 1-(1-4C-alkyl)-1H-imidazolyl, methyl-pyrazinyl or pyridyl-thiazolyl, such as e.g. ~~pyridin 3-yl, pyridin 4-yl, pyrimidin 5-yl, pyrazin 2-yl, 5-methyl-pyrazin 2-yl, isoxazol 5-yl, 1-methyl-imidazol 2-yl, 1-methyl-imidazol 5-yl or 2-(pyridin 3-yl)-thiazol 4-yl,~~

or

Har is substituted by R6 and/or R7 and/or R8, and is pyrimidinyl, in which

R6 is 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

R8 is 1-4C-alkoxy,

~~such as e.g. 2,6-dimethoxypyrimidin 4-yl, 2-methoxy-pyrimidin 5-yl, 2,4,6-trimethoxy pyrimidin 5-yl, 2,4-dimethoxy pyrimidin 5-yl or 2,6-dimethoxy pyrimidin 4-yl,~~

or

Har is substituted by R6, and is pyridinyl, in which

R6 is 1-4C-alkoxycarbonyl,

~~such as e.g. 6-(methoxycarbonyl) pyridin 3-yl or 5-(methoxycarbonyl) pyridin 2-yl,~~

or

Har is substituted by R6, and is pyridinyl, in which

R6 is morpholin-4-yl, piperidin-1-yl, pyrazol-1-yl or imidazol-1-yl,

~~such as e.g. 6 (morpholin-4-yl) pyridin-3-yl, 6 (piperidin-1-yl) pyridin-3-yl, 6 (pyrazol-1-yl) pyridin-3-yl or 6 (imidazol-1-yl) pyridin-3-yl,~~

or

Har is substituted by R6 and/or R7, and is pyridinyl, in which

R6 is 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

~~such as e.g. 2,6 dimethoxy pyridin-4-yl, 2,6 dimethoxy pyridin-3-yl or 2 methoxy pyridin-3-yl,~~

or

Har is substituted by R6 and R7 and R8, and is pyridinyl, in which

R6 is 1-4C-alkoxy,

R7 is 1-4C-alkoxy,

R8 is chlorine,

~~such as e.g. 3-chloro-2,6-dimethoxy pyridin-4-yl;~~

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds.~~

11. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R2 is 1-2C-alkoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen or 1-4C-alkylcarbonyl,

R5 is hydrogen,

Har is optionally substituted by R6 and/or R7 and/or R8, and is a pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl radical, in which

R6 is halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, 1-4C-alkoxycarbonyl, carboxyl, hydroxyl, oxo, or -A-N(R61)R62, in which

A is a bond or 1-4C-alkylene,

R61 is 1-4C-alkyl,

R62 is 1-4C-alkyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl or 4N-methyl-piperazin-1-yl,

or

Het1 is pyrrol-1-yl, pyrazol-1-yl, triazol-1-yl or imidazol-1-yl,

R7 is 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkylthio, hydroxyl, oxo, or di-1-4C-alkylamino,

R8 is halogen, 1-4C-alkyl or 1-4C-alkoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

12. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6, and is pyridinyl, in which

R6 is methoxy, ethoxy, methylthio, methoxycarbonyl, hydroxyl, carboxyl, or -A-N(R61)R62, in which

A is a bond, or ethylene,

R61 is methyl,

R62 is methyl,

or R61 and R62 together and with inclusion of the nitrogen atom, to which they are attached, form a heterocyclic ring Het1, in which

either

Het1 is piperidin-1-yl, pyrrolidin-1-yl or morpholin-4-yl,

or

Het1 is pyrazol-1-yl or imidazol-1-yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

13. (Currently amended) ~~Compounds~~ A compound of formula I

according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is 6-(morpholin-4-yl)-pyridin-3-yl, 6-(piperidin-1-yl)-pyridin-3-yl, 6-(pyrazol-1-yl)-pyridin-3-yl, 6-(imidazol-1-yl)-pyridin-3-yl, 6-methoxycarbonyl-pyridin-3-yl, 3-methoxycarbonyl-pyridin-2-yl, 2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-3-yl, 2-methylsulfanyl-pyridin-3-yl, 6-hydroxy-pyridin-3-yl, 6-carboxy-pyridin-3-yl, 2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl, 2-methylsulfanyl-

pyrimidin-5-yl, 5-methyl-pyrazin-2-yl, or 6-[2-(pyrrolidin-1-yl)-ethyl]-pyridin-3yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N-oxides and the salts of the N-oxides of these compounds and enantiomers.~~

14. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

either

Har is substituted by R6 and R7, and is a pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

R6 is oxo, and

R7 is methyl,

or

R6 is methylthio, and

R7 is methyl,

or

R6 is chlorine, and

R7 is methylthio,

or

R6 is dimethylamino, and

R7 is methoxy or ethoxy,

or

R6 is dimethylamino, and

R7 is dimethylamino,

or

Har is substituted by R6 and R8, and is a pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl radical, in which

R6 is dimethylamino, and

R8 is chlorine,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N-oxides and the salts of the N-oxides of these compounds and enantiomers.~~

15. (Currently amended) ~~Compounds~~ A compound of formula I

according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6 and R7, and is pyridinyl, in which either

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

R6 is oxo, and

R7 is methyl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

16. (Currently amended) ~~Compounds~~ A compound of formula I

according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

either

Har is substituted by R6 and R7, and is pyrimidinyl, in

which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

R6 is oxo, and

R7 is methyl,

or

R6 is methylthio, and

R7 is methyl,

or

R6 is chlorine, and

R7 is methylthio,

or

R6 is dimethylamino, and

R7 is methoxy or ethoxy,

or

Har is substituted by R6 and R8, and is pyrimidinyl, in which

R6 is dimethylamino, and

R8 is chlorine,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

17. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6 and R7, and is pyridazinyl, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N-oxides and the salts of the N-oxides of these compounds and enantiomers.~~

18. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is 2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl, 4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl, 4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl, 1-methyl-1H-pyridin-2-one-5-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl, 4,6-dimethoxy-pyrimidin-5-yl, 4-methyl-2-methylsulfanyl-pyrimidin-5-yl, 5-chloro-2-methylsulfanyl-pyrimidin-4-yl, 4-chloro-2-dimethylamino-pyrimidin-5-yl, 2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-pyrimidin-2-one-5-yl, or 3,6-dimethoxy-pyridazin-4-yl, or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

19. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 in which

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is -O-R41, in which

R41 is hydrogen,

R5 is hydrogen,

Har is any one selected from the group consisting of

6-(imidazol-1-yl)-pyridin-3-yl, pyrimidin-5-yl,

2-methoxy-pyrimidin-5-yl, 2-dimethylamino-pyrimidin-5-yl,

2-methylsulfanyl-pyrimidin-5-yl,

2,6-dimethoxy-pyridin-3-yl, 2,6-dimethoxy-pyridin-4-yl,

4,6-dimethoxy-pyridin-3-yl, 5,6-dimethoxy-pyridin-3-yl,

4,6-diethoxy-pyridin-3-yl, 5-ethoxy-6-methoxy-pyridin-3-yl,

1-methyl-1H-pyridin-2-one-5-yl,

2,6-dimethoxy-pyrimidin-4-yl, 2,4-dimethoxy-pyrimidin-5-yl,

4,6-dimethoxy-pyrimidin-5-yl,

2-dimethylamino-4-methoxy-pyrimidin-5-yl, 1-methyl-1H-

pyrimidin-2-one-5-yl, and

3,6-dimethoxy-pyridazin-4-yl,

or a salt, enantiomer, N-oxide, salt of an N-oxide or

enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

20. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 ~~any of the preceding claims~~ comprising one or more of the following:

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy, and

R3 and R31 are both hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen, [[;]]

Har is substituted by R6 and R7, and is pyridinyl, [[;]] and

Har is optionally substituted by R6 and/or R7, and is pyrimidinyl or pyridazinyl, [[;]]

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

21. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 ~~any of the preceding claims~~ comprising one or more of the following:

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy, and

R3 and R31 are both hydrogen, [[;]]

R4 is -O-R41, in which

R41 is hydrogen, and

R5 is hydrogen, [[;]] and

Har is either N-methyl-pyrid-2-onyl or N-methyl-pyrimid-2-onyl,

or imidazol-1-yl-pyridinyl or pyrazol-1-yl-pyridinyl,

or methylthio-pyrimidinyl, methoxy-pyrimidinyl,

dimethylamino-pyrimidinyl or pyrimidinyl,

or

Har is substituted by R6 and R7, and is pyridinyl, in which

R6 is methoxy or ethoxy, and

R7 is methoxy or ethoxy,

or

Har is substituted by R6 and R7, and is pyrimidinyl or pyridazinyl, in which

R6 is methoxy, ethoxy or dimethylamino, and

R7 is methoxy or ethoxy, [[;]]

or a salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof

~~and the enantiomers, as well as the salts, the N oxides and the salts of the N oxides of these compounds and enantiomers.~~

22. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1 which is ~~[[are]]~~ selected from the group consisting of

(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(3-methyl-3H-imidazol-4-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(2-pyridin-3-yl-thiazol-4-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-6-isoxazol-5-yl-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-pyridin-4-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-

phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-9-(1,1-difluoro-methoxy)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-9-(2,2-difluoro-ethoxy)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,3]dioxol-5-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzothiazol-6-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8,9-Dimethoxy-6-quinolin-6-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(1-methyl-1H-imidazol-2-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

5-((2RS,4aRS,10bRS)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-pyridine-2-carboxylic acid methyl ester,

(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-6-(2,6-dimethoxypyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-8-methoxy-6-(2-methoxypyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-8-methoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-8-methoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-(2,2-Difluoro-ethoxy)-6-(2,6-dimethoxypyrimidin-4-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8-(2,2-Difluoro-ethoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(3-Chloro-2,6-dimethoxy-pyridin-4-yl)-9-(2,2-difluoro-ethoxy)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-pyrimidin-5-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(6-pyrazol-1-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

6-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-nicotinic acid methyl ester,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methoxy-pyrimidin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2,4,6-trimethoxy-pyrimidin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2,4-Dimethoxy-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(5-methyl-pyrazin-2-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-6-(6-imidazol-1-yl-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-pyrazin-2-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(1-methyl-1H-benzotriazol-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2S,4aS,10bS)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(3SR,4aRS,10bRS)-8,9-Dimethoxy-6-pyridin-3-yl-
1,2,3,4,4a,10b-hexahydro-phenanthridin-3-ol,
(2R,4aR,10bR)-6-(4-Chloro-2,6-dimethoxy-pyridin-3-yl)-9-
ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-
ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methylsulfanyl-
pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(4-methyl-2-
methylsulfanyl-pyrimidin-5-yl)-1,2,3,4,4a,10b-hexahydro-
phenanthridin-2-ol,
(2R,4aR,10bR)-6-(5-Chloro-2-methylsulfanyl-pyrimidin-4-yl)-
9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-
2-ol,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methoxy-pyridin-3-
yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-
1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-
pyridin-2-one,
(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(6-methoxy-pyridin-3-
yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,
(2R,4aR,10bR)-6-(4-Chloro-2-dimethylamino-pyrimidin-5-yl)-
9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-
2-ol,

(2R,4aR,10bR)-6-(2-Dimethylamino-4-methoxy-pyrimidin-5-yl)-
9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-
2-ol,

(2R,4aR,10bR)-6-(4,6-Diethoxy-pyridin-3-yl)-9-ethoxy-8-
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(4,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2-Dimethylamino-pyrimidin-5-yl)-9-ethoxy-8-
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(5,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-6-(5-ethoxy-6-methoxy-pyridin-3-yl)-
8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-9-Ethoxy-8-methoxy-6-(2-methylsulfonyl-
pyrimidin-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-
1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-
pyrimidin-2-one,

(2R,4aR,10bR)-9-Ethoxy-6-(6-hydroxy-pyridin-3-yl)-8-
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(3,6-Dimethoxy-pyridazin-4-yl)-9-ethoxy-8-
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(4,6-Dimethoxy-pyrimidin-5-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyridin-4-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-(1,1-Difluoro-methoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8-(1,1-Difluoro-methoxy)-6-(2,6-dimethoxy-pyridin-3-yl)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,5]oxadiazol-5-yl-8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(2,6-Dimethoxy-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(5-Chloro-2,6-bis-dimethylamino-pyrimidin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyrimidin-5-yl-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-pyrazin-2-yl-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(5-Chloro-4-methyl-3,4-dihydro-2H-

benzo[1,4]oxazin-7-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(6-pyrazol-1-yl-

pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-6-(6-imidazol-1-yl-pyridin-3-yl)-

8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-Benzo[1,2,3]thiadiazol-5-yl-9-ethoxy-8-

methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-[6-(2-pyrrolidin-1-

yl-ethyl)-pyridin-3-yl]-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(2-methoxy-pyridin-3-

yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-(1-methyl-1H-

benzotriazol-5-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-9-Ethoxy-8-methoxy-6-quinoxalin-5-yl-

1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-6-(3-Chloro-2,6-dimethoxy-pyridin-4-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8-(1,1-Difluoro-methoxy)-9-methoxy-6-pyridin-3-yl-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2RS,4aRS,10bRS)-8-(1,1-Difluoro-methoxy)-9-methoxy-6-(6-morpholin-4-yl-pyridin-3-yl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

~~5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4^a,10b-hexahydro-phenanthridin-6-yl)-pyridine-2-carboxylic acid~~

5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-pyridine-2-carboxylic acid,


(2S,4aS,10bS)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-8,9-dimethoxy-1,2,3,4,4^a,10b-hexahydro-phenanthridin-2-ol, **[[and]]**

(3SR,4aRS,10bRS)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-3-ol,
and the salts, enantiomers, N-oxides, salts of the N-oxides
and enantiomers thereof

~~and the enantiomers, as well as the salts, the N-oxides and the salts of the N-oxides of these compounds and enantiomers.~~

23. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1, which has ~~any of the preceding claims, which have~~ with respect to the positions 4a and 10b the configuration shown in formula I*:





or a salt, N-oxide or salt of an N-oxide thereof

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds.~~

24. (Currently amended) ~~Compounds~~ A compound of formula I according to claim 1, which has ~~any of the preceding claims, which have~~ with respect to the positions 2, 4a and 10b the configuration shown in formula Ia*****, or, which

[[have]] has with respect to the positions 3, 4a and 10b the configuration shown in formula Ib*****:



or a salt, N-oxide or salt of an N-oxide thereof
~~and the salts, the N-oxides and the salts of the N-oxides~~
~~of these compounds.~~

25. (Canceled)

26. (Currently amended) A pharmaceutical composition comprising one or more compounds of formula I as claimed in claim 1, or a pharmaceutically acceptable salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof, together with a pharmaceutically acceptable excipient and/or vehicle
~~customary pharmaceutical excipients and/or vehicles.~~

27. - 28. (Canceled)

29. (Currently amended) A method for treating an illness ~~illnesses~~ in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

30. (Currently amended) A method for treating an airway ~~disorders~~ disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.

31. (New) A method for treating a PDE-mediated disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I as claimed in claim 1, or a pharmaceutically acceptable salt, enantiomer, N-oxide, salt of an N-oxide or enantiomer thereof.